NAL 3221

Drug Profile

NAL 3221

Alternative Names: NAL3221

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator NAL Pharma
  • Class Anti-infectives; Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Herpes zoster

Most Recent Events

  • 09 Sep 2016 Discontinued - Clinical-Phase-Unknown for Herpes zoster (Topical)
  • 16 Aug 2016 Clinical trials in Herpes zoster (Topical)
  • 16 Aug 2016 NAL 3221 is available for licensing as of 16 Aug 2016. http://www.nalpharma.com/licensing.php?id=10&lang=en
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top